Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | IDE | P14735 | 1/20 | 0.47 |
| ▸ | MPI | P34949 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.44 |
| ▸ | DAO | P14920 | 5/20 | 0.43 |
| ▸ | DDO | Q99489 | 4/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16992592 | 0.84 | GRIN1 (0.48) | KDM4EMAPTALDH1A1IDEMPI | |
| SCHEMBL9389356 | 0.77 | DAO (0.50) | CDK1CDK2DAODDOGPR17 | |
| SCHEMBL1276512 | 0.76 | KDM4E (0.69) | KDM4EMAPTALDH1A1IDEMPI | |
| SCHEMBL6645136 | 0.73 | KDM4E (0.48) | KDM4EALDH1A1CDK1CDK2GRIN2D | |
| SCHEMBL2733263 | 0.73 | GPR17 (0.61) | KDM4EALDH1A1GPR17PARP1 | |
| SCHEMBL20247290 | 0.70 | PDPK1 (0.41) | KDM4EMAPTALDH1A1CDK1CDK2 | |
| SCHEMBL3360284 | 0.68 | GRIN2D (0.60) | KDM4EMAPTALDH1A1IDEMPI | |
| SCHEMBL3422204 | 0.67 | DAO (0.49) | KDM4EMAPTALDH1A1IDEMPI | |
| SCHEMBL5310423 | 0.67 | F2 (0.52) | CDK1CDK2GPR17 | |
| SCHEMBL9452228 | 0.66 | HPGD (0.57) | KDM4EMAPTALDH1A1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240122859-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | NOKHA TRADING LLP (IN) | 2024-04-18 | — | — | US | claimed |
| WO-2022172225-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | LYRUS LIFE SCIENCES PVT. LTD. (IN) | 2022-08-18 | — | — | WO | claimed |
| US-20250367232-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | HUTCHINSON FRED CANCER RES (US) | 2025-12-04 | — | — | US | disclosed |
| US-12016880-B2 | Halogen treatment of heart attack and ischemic injury | FRED HUTCHINSON CANCER CENTER (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3104939-B1 | TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY WITH SODIUM IODIDE | FRED HUTCHINSON CANCER CENTER (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240122859-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | NOKHA TRADING LLP (IN) | 2024-04-18 | — | — | US | disclosed |
| US-20220387483-A1 | USE OF IODIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY-ASSOCIATED CACHEXIA AND CARDIOTOXICITY | FARADAY PHARMACEUTICALS INC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220313730-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | FRED HUTCHINSON CANCER CENTER | 2022-10-06 | — | — | US | disclosed |
| EP-4054593-A1 | USE OF IODIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY-ASSOCIATED CACHEXIA AND CARDIOTOXICITY | Faraday Pharmaceuticals, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114929246-A | Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity | 法拉第制药公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022172225-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | LYRUS LIFE SCIENCES PVT. LTD. (IN) | 2022-08-18 | — | — | WO | disclosed |
| EP-3801565-A1 | USE OF HALOGEN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF TISSUE INJURY AND POST-INTENSIVE CARE SYNDROME | Faraday Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-106102836-B | Halogen treatment of heart attack and ischemic injury | 弗雷德哈钦森癌症研究中心 | 2020-02-04 | — | — | CN | disclosed |
| US-10201570-B2 | Halogen treatment of heart attack and ischemic injury | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2019-02-12 | — | — | US | disclosed |
| EP-3104939-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | Fred Hutchinson Cancer Research Center (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160346323-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | FRED HUTCHINSON CANCER CENTER | 2016-12-01 | — | — | US | disclosed |
| WO-2015120458-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2015-08-13 | — | — | WO | disclosed |
| EP-1895959-A1 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070110685-A1 | Combination therapy for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2006138518-A1 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070110685-A1 | Combination therapy for the treatment of immunoinflammatory disorders | SERPINC1, SERPINA6, IL36G | KDM4E 4830/4885MAPT 231/4885ALDH1A1 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.